Astral Codex Ten

Yale

18 min read

Yale

Article

Yale is a recurring place in the Astral Codex Ten archive, appearing 2 times across 2 issues between March 27, 2022 and June 18, 2025. The archive places it in contexts such as “Yale: 4/22–4/23”; “former Yale grad”. It most often appears alongside Baltimore, California, Metaculus.

Metadata

  • Category: Places
  • Mention count: 2
  • Issue count: 2
  • First seen: March 27, 2022
  • Last seen: June 18, 2025

Appears In

Source Context

Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.

Open Thread 217
March 27, 2022 · Original source
Metaculus currently has him at 40% to win the primary and 29% to win the general. I’m closer to 60/45. Although he’s getting support from some big funders, campaign finance privileges small-to-medium-sized donations from ordinary people. If you want to support him, you can see a list of possible options here - including donations. You can donate max $2900 for the primary, plus another $2900 for the general that will be refunded if he doesn’t make it. If you do donate, it would be extra helpful if the money came in before a key reporting deadline March 31. 3: Every year in autumn I hold a big Meetups Everywhere event, and every time people tell me I should do it more often than once a year. So this time we’ll hold a mini-Meetups-Everywhere this April. It won’t be any different from your usual meetup schedule except that it’ll be the Schelling time for everyone who only wants to come once every few months to come. If you’re a meetups organizer (or want to become one), please fill in this form with the date of a meetup April 11th or later. Next Sunday I’ll put the results on the Open Thread for people to see. 4: Speaking of meetups, the rationalist/EA establishment is trying to promote local meetups. If you’re a local ACX/LW meetups organizer, you’re potentially invited to attend an all-expenses paid retreat in California in July with our meetups czar Mingyuan. Please read more here, then fill in this form to get on her radar. 5: And speaking of Mingyuan, she is going to inspect - sorry, enjoy the hospitality of - the East Coast meetup groups. She’ll be in DC: 4/11–4/13 Baltimore: 4/14 Philadelphia: 4/15–4/16 NYC: 4/17–4/21 Yale: 4/22–4/23 Northampton: 4/24–4/25 Boston: 4/26–5/1. The local groups have already taken care of having meetups at the right time, but she’s looking for people who could host her and drive her between cities . Email meetupsmingyuan@gmail.com if you can help. 6: Last week I tried to figure out the needs of community members in Russia and Ukraine. There are some great resources on the thread, but issues that still need solving: Seven Ukrainian refugees looking for remote work
Inline links: here, donations., fill in this form, here, this form, on the thread, Seven Ukrainian refugees looking for remote work
ACX Grants 1-3 Year Updates
June 18, 2025 · Original source
Since 2022, Alice has undertaken qualitative research in nine world regions: Mexico, Costa Rica, Brazil, Morocco, Italy, Spain, Britain, US, Poland, Turkey, India, Uzbekistan, South Korea and Hong Kong. Through this globally comparative analysis, she analyses the drivers and obstacles to gender equality. Gender interventions will be more impactful if they target locally binding constraints - in the Middle East, North Africa and South Asia, this is "the honour-income trade-off" (whereby male honour depends on female seclusion, and women tend to remain at home. Meanwhile, Latin America and the Caribbean face a different obstacle: pervasive violence elevates femicides. Over the past few years, she's held visiting appointments at Stanford, Chicago, and Yale, while providing policy advice to the World Bank, and sharing insights with a public audience via Substack (www.ggd.world). In April 2025, she gave a TedTalk on romantic love as an under-rated driver of gender equality.
Minnesota and Virginia also have legislation to enable cities to implement land value taxes. We are monitoring these efforts. There are a few other cities we are operating in. We have helped another organization prepare for a meeting in Tennessee by doing impact analysis of land value taxes in the city. We have presented to city officials in the City of South Bend who have expressed support for land value taxes. Finally, we are in conversation with a State Senator in Colorado who is a champion of land value taxes. Meanwhile, we have soft launched and developed the OpenAVMKit, which uses a unified schema to do assessment accuracy reports and automated valuation methods for any property tax data given. Valuation of land is the key binding constraint to successful implementation of land value taxes. We plan to be the leaders in this space with strong benchmarking capabilities and a repo that can enable the open-source community to make the best automated valuation methods. Along with these efforts, we have expanded the movement. We have posted to the Progress and Poverty Substack growing the subscriber base to around 5,000 subscribers. We have spoken to over 25 local advocates interested in working on land value taxes in their local communities. Yet, there is a long way to go. We need to start earning income through technical assistance contracts as our grant funding expires. We need to continue pushing for a state to implement, and we need to be prepared to tell the success story for when they do. 65: EN’s Work On Bacteriophage Therapy Our project is aimed at pioneering phage therapy in Nigeria, where limited resources/infrastructure have historically held back research in this field. Starting from the ground up, we are establishing the foundational systems needed to support a robust phage research ecosystem. So far, we’ve isolated 34 bacteriophages targeting Pseudomonas aeruginosa, an essential step toward building a comprehensive phage bank. This began with collecting a wide range of clinical Pseudomonas isolates, which we are now characterizing alongside the phages through genome sequencing and phenotypic assays including studies on phage stability across pH, temperature, and salinity ranges. Our long-term goal is to develop a phage-based hydrogel for treating diabetic wounds. On the regulatory front, we have secured approval from the Attorney General to register our nonprofit organization, the Centre for Phage Biology and Therapeutics. Additionally, we’re expanding into vaccine development; following a research stay in Prof. Roderick's lab at the University of Waterloo, we have initiated the design of a phage-based universal Salmonella vaccine aimed at covering all major serotypes—an urgent need underscored by Africa’s reliance on external vaccine sources during the COVID-19 pandemic. I have signed an MTA agreement with Roderick to use his phage-based vaccine platform patents to enable us to design vaccines against any common disease affecting us. This is only the beginning, but we are proud to be laying the scientific and institutional groundwork for homegrown phage innovation in Africa. Emergent Ventures funded EN before we did and deserves a lot of credit here also. 66: Create An Artificial Kidney For an implantable artificial kidney, the first essential component is a hemofilter designed to emulate the glomerulus. Critical requirements for this hemofilter include high permeability (to maximize flow for a given area), selectivity (specifically, the retention of albumin), and robust blood compatibility (ensuring sustained function over time). Our initial strategy focused on using negative surface charge to reduce fouling. I began by testing polyelectrolyte (PE) coatings on 24nm pore membranes featuring a negative terminal charge, similar to the glomerular barrier. These initial static tests, assessing platelet adsorption in whole blood, yielded positive outcomes for some polyelectrolytes, indicating potentially desirable blood compatibility. However, static test setups are not truly representative of dynamic in-vitro conditions and don't provide data on key parameters like permeability, fouling progression, or changes in membrane selectivity. To address these limitations, I designed and built a blood filtration setup. This system sustains human whole blood in circulation for 20 minutes, allowing us to analyze all the aforementioned parameters, as well as platelet activation markers. This has resulted in a fairly high-throughput system for evaluating any surface coating. I'm pleased to report this setup has been accepted for presentation at this year's European Society for Artificial Organs (ESAIO) conference. I am also currently working on a full manuscript, as I believe this system offers a viable way to partially replace animal experiments in our early-stage research, requiring only 1.2ml of human blood per run. Working with a PhD student (hired to support both this research and work on membrane substrates), we have continued testing these PE coatings, alongside PEG coatings, on our membranes. Here, we're finding that optimization of the coating layer is crucial. With the current PE coatings, we observe a permeability drop of about an order of magnitude compared to the base membrane, making them unsuitable for an implantable device in their present form. This is likely due to the specific nature of the initial PE layer, which we can modify. We also suspect there may be ingress of PE into the pores, meaning we're not achieving just a surface coating (our goal), but rather a very thick coating, which would explain the flux loss. Optimizing the coating process to control penetration depth is now a primary focus of my ongoing work. I am currently aiming for a flux of 20ul/min (as this is cap introduced by the protein gel layer anyway) but for it to be at this 'steady state' permeability without drop in permeability. I am also imaging the membranes after contact with SEM to see if there is indeed any platelet adsorption etc. Tugrul has the dubious honor of maybe being "the only person to climb a 4000m peak with severe kidney failure". To raise money and awareness for his artificial kidney project, he is running Climb Against Time, where he will climb 41 mountains over 4000m (13000 ft) this summer. He is looking for donors and climbing partners. 67: Add Tardigrade Genes To Human Cells The goal of this one was to make hybrid cells that are more resilient for research and certain medical applications. They report: The grant was to synthesize vectors for the expression of humanized tardigrade proteins that can be targeted to different areas of the cell. All the vectors were designed, generated, and transposed into human cells. The proteins all localize successfully (e.g. they match the designed target), with one exception (we are still working on validating it). We've done some stress testing with the trangenic cells, but haven't reached firm conclusions yet. We've further generated some multigene designs but have not yet transposed them into cells, but should shortly. We're hoping to submit a manuscript on the first round later this year. 68: Teach Forecasting To EU Policy-Makers The original project didn't work out, but our grantee (who still prefers to remain anonymous) is now working with an EU think tank pursuing the same agenda, and has been teaching forecasting workshops to policy-makers for the past two months. 69: Platform For Single-Cell Imaging They ended up unable to accept this grant and returned the money. 70: Open Source Polygenic Predictor For EA/IQ They have an update here. They think they have a predictor that can explain 12% of variance in intelligence, and they’re working on validating it and creating an easy-to-use website. 71: Improve Flu Vaccines The grant mainly funded agent based modelling to demonstrate the benefit of pre-existing immunity to pandemic influenza if and when a future pandemic occurs (academic publication will result). The original proposal was to attempt to influence the WHO influenza strain selection process. After attending WHO meetings and a global influenza conference, I believe this is not feasible. Stakeholder feedback was the potential short term negative effect on vaccine hesitancy is believed to outweigh the less tangible future benefit. Given the conservative nature of decision makers, pandemic vaccines are likely to remain research only. There are still green shoots of research into pandemic preparedness/prevention that I am continuing to work on. I'm working under the "Australians for Pandemic Prevention" brand of Good Ancestors, another group that ACX funded in 2024. 72: Scenario Analysis For Developing World Agricultural Programs In addition to the research and analysis funded by the grant, I’ve learned to code with LLMs and have built an MVP of the project. The app is being considered for further development by staff at a large international organization. 73: Further C’s Political Career C’s political career is going well, but he continues to think it wouldn’t be strategic to give more information publicly at this time. Lessons Learned I'm most impressed with our lobbying/advocacy organizations. In particular, Good Ancestors has gotten the Australian government to sign onto an international AI safety declaration, partner with various x-risk-related organizations, and (possibly) extend charity tax deductions to some EA causes that previously didn't have it - I think this on its own goes a substantial way to paying back the cost of all ACX Grants. Coalition to Modify NOTA has a kidney donation bill in front of Congress that the (very illiquid) prediction markets give a 45% chance of passing; if it works, it could save thousands of lives. The Georgists are partly responsible for bills making land value taxes slightly easier to implement in a handful of states. Good Science Project seems to have significantly improved science. Are lobbying organizations a better bet than other types of nonprofit (within the constraints of ACX Grants)? I'm not sure. It could just be that lobbyists are (naturally) better at playing themselves up and sounding successful than (for example) scientists, or that politicians are good at people-pleasing and make people feel heard and encouraged in a way that might not change overall policy later. Also, I recently talked to some grantmakers who funded a lobbying organization that superficially seems excellent, but they expressed concern it was net negative (!) by taking away oxygen and spotlight from potentially more effective orgs. So I am encouraged but wary. Animal welfare organizations were another standout success. Again, I don't know how to think about this - while I think our grantees were exceptional, there's also an issue where the scale of animal welfare challenges is so great, and work on them so neglected, that lots of organizations can save a million chickens here, or a million fish there, without particularly making a splash. On the one hand, this is exactly what effective altruism should be doing - exploring grants that are very high in linear utility even if they don't feel satisfying. On the other, they're unsatisfying - and also hard to assess retroactively. How many chickens should a good animal welfare grant save? Any realistic number will both be overwhelmingly large in absolute terms and far too small in relative terms. I'm most ambivalent about our science grants. Many of them say they are successful and can point to published papers which explain the science they did. But it's hard to judge whether anything useful has changed based on the science getting done. I know it's important to fund basic research and not just last-mile technology startups, but it's hard for a mini-grants program like this one to evaluate these kinds of abstract interventions. One disappointing result was that grants to legibly-credentialled people operating in high-status ways usually did better than betting on small scrappy startups (whether companies or nonprofits). For example, Innovate Animal Ag was in many ways overdetermined as a grantee - former Yale grad and Google engineer founder, profiled in NYT, already funded by Open Philanthropy - and they in fact did amazing work. On the other hand, there were a lot of promising ACX community members with interesting ideas who were going to turn them into startups any day now, but who ended up kind of floundering (although this also describes Manifold, one of our standout successes). One thing I still don't understand is that Innovate Animal Ag seemed to genuinely need more funding despite being legibly great and high status - does this screen off a theoretical objection that they don't provide ACX Grants with as much counterfactual impact? Am I really just mad that it would be boring to give too many grants to obviously-good things that even moron could spot as promising? Someone (I think it might be Paul Graham) once said that they were always surprised how quickly destined-to-be-successful startup founders responded to emails - sometimes within a single-digit number of minutes regardless of time of day. I used to think of this as mysterious - some sort of psychological trait? Working with these grants has made me think of it as just a straightforward fact of life: some people operate an order of magnitude faster than others. The Manifold team created something like five different novel institutions in the amount of time it's taken some other grantees to figure out a business plan; I particularly remember one time when I needed something, sent out a request to talk about it with two or three different teams, and the Manifold team had fully created the thing and were pestering me to launch a trial version before some of the other people had even gotten back to me. I take no pleasure in reporting this - I sometimes take a week or two to answer emails, and all of the predictions about my personality that this implies would be correct - but it's increasingly something that I look for and respect. A lot of the most successful grants succeeded quickly, or at least were quick to get on a promising track. Since everything takes ten times longer than people expect, only someone who moves ten times faster than people expect can get things done in a reasonable amount of time. In almost every case where I thought to myself “this is a cool idea, but I don’t know how it’s going to really pay off, as opposed to reaching a cool intermediate accomplishment and then stagnating”, this was a correct criticism, and I should have taken it more seriously. But I can’t rule out that these were good in vague and hard-to-measure ways that I should take more seriously. This one is really self-serving, but in general when people were good communicators (or even bloggers) and wowed me with the writing-composition of their application, they turned out to be a good bet. And when people were hard to understand and annoying to communicate with, even if their ideas seemed good, they were less likely to pan out. Overall Thoughts The total cost of ACX Grants, both rounds, was about $3 million. Do these outcomes represent a successful use of that amount of money? Very naively, startups originating from ACX Grants have about $50 million in value1. If ACX Grants is equivalent to a pre-seed funder, and pre-seed funders usually get ~5%, then if we were VCs we would have a portfolio worth $2.5 million. About 1/5 of ACX Grants were attempting to be market-valued startups, so if we assume the charitable portion did about as well as the startup portion, then the charity portion is “worth” $10 million. There’s some reason to expect this is too high, since much of the startup value came from one successful outlier. But there’s another reason to expect this is too low, since we were aiming at charity rather than market cap, and any actual market cap that our grantees got was an unexpected side effect. I’m treating this as a sanity check rather than as a real number. It’s harder to produce Inside View estimates, because so many of the projects either produce vague deliverables (eg a white paper that might guide future action) or intermediate results only (eg getting a government to pass AI safety regulations is good, but can’t be considered an end result unless those regulations prevent the AI apocalypse). Because we tend towards incubating charities and funding research (rather than last-mile causes like buying bednets), achieved measurable deliverables are thin on the ground. But here are things that ACX grantees have already accomplished: Improved the living/slaughter conditions of 30 million fish.
Inline links: Progress and Poverty Substack, Climb Against Time, here, 1